Home Back

MDS Revised - International Prognostic Scoring System (IPSS-R)

Age
years
Bone Marrow Blast Percentage
Please select
Bone Marrow Blast Percentage
0-2%
2%-5%
5%-10%
>10%
Cytogenetics
Please select
Cytogenetics
Very Good
Good
Intermediate
Poor
Very Poor
Hemoglobin
Please select
Hemoglobin
≥100g/L
80g/L-100g/L
<80g/L
Absolute Neutrophil Count
Please select
Absolute Neutrophil Count
≥0.8 ×109/L
<0.8 ×109/L
Platelet Count
Please select
Platelet Count
≥100 ×109/L
50-100 ×109/L
<50 ×109/L
Score:
Risk Level:
Median Survival:

Result Interpretation

Assess the mortality and risk of progression to acute myeloid leukemia in myelodysplastic syndromes

Myelodysplastic syndromes are a group of heterogeneous diseases with different prognoses. To improve the original IPSS, the international MDS database was combined for analysis (database sample size n=7012). Prognostic risk modeling is based on multivariate analysis of patient survival time and AML transformation time.

In the revised IPSS scoring system, bone marrow cell genetics, bone marrow blast percentage, and cytopenias remain the three basic indicators, but the classification thresholds have been improved and age, patient baseline status, serum ferritin, and LDH have been added.

References

Research Paper The original IPSS was proposed and validated by revised/developed by Greenberg et al. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood 1997;89:2079-2088 Research Paper The revised model was developed by Greenberg et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood 2012;120(12):2454-2465).
Favorite